GILD Earnings & Financial Statements
Gilead Sciences, Inc.
$151.17
+$4.07(+2.77%)
63
Overall
80
Value
50
Tech
60
Quality
Market Cap
$182.40B
Volume
5.33M
52W Range
$112.41 - $157.29
Target Price
$159.41
GILD earnings and financial statements: Gilead Sciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GILD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B |
| Cost of revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B |
| EBITDA | $13.58B | $4.43B | $10.50B | $8.85B | $11.33B |
| Net income | $8.51B | $480.00M | $5.67B | $4.59B | $6.22B |
| EPS (diluted) | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B | $67.95B |
| Total liabilities | $32.07B | $35.86B | $39.38B | $41.96B | $46.89B |
| Shareholders’ equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B |
| Cash and equivalents | - | - | - | $5.41B | $5.34B |
| Long-term debt | $22.13B | $24.90B | $23.19B | $22.96B | $25.18B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B |
| Capital expenditure | -$563.00M | -$523.00M | -$585.00M | -$728.00M | -$579.00M |
| Free cash flow | $9.46B | $10.30B | $7.42B | $8.34B | $10.80B |
| Dividends paid | $4.00B | $3.92B | $3.81B | $3.71B | $3.60B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GILD | $151.17 | +2.8% | 5.33M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |